Processa Pharmaceuticals ... (PCSA)
NASDAQ: PCSA
· Real-Time Price · USD
0.24
-0.00 (-1.40%)
At close: May 23, 2025, 2:28 PM
-1.40% (1D)
Bid | 0.24 |
Market Cap | 2.88M |
Revenue (ttm) | n/a |
Net Income (ttm) | -11.96M |
EPS (ttm) | -3.06 |
PE Ratio (ttm) | -0.08 |
Forward PE | -0.28 |
Analyst | Buy |
Ask | 0.24 |
Volume | 8,478,816 |
Avg. Volume (20D) | 2,566,490 |
Open | 0.25 |
Previous Close | 0.24 |
Day's Range | 0.23 - 0.32 |
52-Week Range | 0.15 - 3.10 |
Beta | 1.35 |
About PCSA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol PCSA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for PCSA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 months ago
-3.7%
Processa Pharmaceuticals shares are trading lower ...
Unlock content with
Pro Subscription
7 months ago
+0%
Processa Pharmaceuticals shares are trading higher after the company announced the dosing of its first patient for the Phase 2 trial of NGC-Cap.

2 years ago · seekingalpha.com
Processa Pharmaceuticals, Inc. (PCSA) Q3 2022 Earnings Call TranscriptProcessa Pharmaceuticals, Inc. (NASDAQ:PCSA ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Jim Stanker - CFO David Young - President & CEO Conference Call Particip...